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  A
polipoprotein E (apoE) 
has effects on lipoprotein 
metabolism and the vasculature 
that have long been considered to be 
anti-atherogenic [1]. In the plasma, 
apoE is found on the surface of 
triglyceride-rich lipoproteins, such as 
very low density lipoproteins (VLDL) 
and remnant particles. ApoE is also 
found on high density lipoproteins 
(HDL) and as such may serve distinct 
functions depending on its speciﬁ  c 
lipoprotein association.  
  Anti-Atherogenic  Properties  of 
ApoE
    ApoE is the main ligand for clearance 
of triglyceride rich particles via the low 
density lipoprotein receptor (LDLR) 
and related receptors in the liver, 
thereby regulating plasma levels of 
these lipoproteins and thus also of 
plasma cholesterol and triglyceride 
levels. In mice, apoE gene deletion 
results in severe hypercholesterolemia, 
due to accumulation of VLDL and 
remnant particles, and in accelerated 
atherosclerosis. In humans, there are 
two common apoE polymorphisms, 
apoE2 and apoE4, that affect its 
function compared with the wild-type 
apoE3 and that have been extensively 
studied (sidebar) [2]. While these 
common genetic variants of apoE 
clearly affect lipoprotein metabolism 
and risk of atherosclerosis, they 
account for only a limited portion of 
the variability in plasma apoE levels. 
    ApoE is believed to have additional 
properties beyond regulation of 
lipoprotein remnant clearance that 
have been historically considered 
anti-atherogenic in nature [3]. For 
example, in LDLR-deﬁ  cient mice, 
hepatic overexpression of apoE 
was shown to induce regression of 
atherosclerosis without affecting 
plasma lipoprotein levels [4]. 
Extrahepatic apoE expression has 
been shown to inhibit atherosclerosis 
in otherwise apoE-deﬁ  cient mice 
without inﬂ  uencing cholesterol 
levels [5,6]. Additional potentially 
anti-atherogenic properties of apoE 
include promotion of macrophage 
cholesterol efﬂ  ux [7], inhibition of T 
cell [8] and vascular smooth muscle 
cell [9] proliferation, and antioxidant 
effects [10]. Furthermore, apoE 
reduces the inﬂ  ammatory response 
during experimental endotoxemia in 
mice [11,12], supporting a role for 
apoE in limiting innate inﬂ  ammatory 
responses to exogenous antigens. 
The mechanisms for many of 
the pleitropic effects are not well 
understood. Nevertheless, based on 
these properties, apoE has been widely 
considered to be anti-atherogenic [3].
    The Association between ApoE and 
Atherosclerosis
    In this context, Mooijaart and 
colleagues present novel data in   PLoS 
Medicine   that should stimulate more 
intense examination of the role of 
apoE in human atherosclerosis [13]. 
They report, for the ﬁ  rst time, a 
surprising positive relationship between 
plasma apoE levels and cardiovascular 
mortality. They used the Leiden 85-plus 
Study, a prospective study of 546 elderly 
people over the age of 85 at time of 
recruitment and followed prospectively 
for mortality.  
    The study provides clear evidence 
for the direct association of apoE 
levels with cardiovascular disease 
(CVD) mortality in this cohort, and 
also shows that this association is 
independent of apoE genotype. The 
study also highlights the remarkable 
paucity of data on the relationship 
between plasma apoE levels and CVD 
and outcomes in humans and suggests 
that this issue should be studied in 
additional observational studies and 
even in interventional clinical trials. 
  Unanswered  Questions
    However, Mooijaart and colleagues’s 
study leaves several unanswered 
questions that need to be addressed 
in future studies. It is possible that 
plasma apoE levels may have been 
simply a surrogate for plasma levels 
of atherogenic remnant lipoprotein 
particles, which were not measured as 
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  Common ApoE Polymorphisms
   ApoE2:  exhibits   reduced  afﬁ  nity for 
the LDLR, with reduced clearance of 
apoE-containing remnant lipoproteins. 
Individuals homozygous for apoE2/
E2 have higher plasma apoE levels, 
often develop hyperlipidemia due to 
accumulation of remnant lipoproteins, 
and are at risk for premature 
atherosclerotic disease. 
   ApoE4:  has   increased  LDLR afﬁ  nity with 
more rapid clearance of apoE-containing 
remnant lipoproteins. Carriers of apoE4 
have lower plasma apoE levels, but 
increased LDL cholesterol levels and 
increased cardiovascular risk. 
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part of this study. Several other studies 
have shown that direct measures of 
remnant particles provide independent 
value in predicting CVD beyond 
traditional lipoprotein measures 
[14]. Furthermore, apoE in plasma 
is distributed among remnant apoB-
containing lipoproteins and HDL. 
Attempts to quantitate apoE in each 
of these major fractions, rather than 
just in total plasma apoE, would have 
provided critical information on the 
relationship of remnant apoE versus 
HDL apoE to CVD mortality. 
    The authors suggest that apoE may 
actually be pro-atherogenic in humans 
and thus causally linked to the increased 
CVD mortality in people with higher 
apoE levels. This runs counter to 
current dogma that apoE is on balance 
anti-atherogenic. However, a speciﬁ  c 
pro-inﬂ  ammatory role for apoE has 
been suggested by recent work. Elzen 
and colleagues [15] recently reported 
that apoE can mediate exogenous 
lipid antigen presentation to antigen-
presenting cells (APCs), possibly via 
LDL receptor–dependent endocytosis 
and delivery to CD1 containing 
endosomes in APCs, thus stimulating 
systemic immune responses. In this 
capacity, apoE can be secreted by 
APCs as a mechanism to survey the 
local environment to capture antigens 
or to transfer microbial lipids from 
infected cells to bystander APCs and 
dendritic cells. In their paper, Elzen and 
colleagues went so far as to speculate 
that, in addition to presenting foreign 
lipids, apoE may be involved in the 
delivery of self-lipid antigens and 
therefore contribute to inﬂ  ammatory 
responses in diseases such as 
atherosclerosis. This hypothesis requires 
direct testing in atherosclerotic models. 
In fact, it remains to be established that 
the antigen-presenting function of apoE 
is, in fact, pro-atherogenic; it is possible 
that it might serve atheroprotective 
functions by removing antigenic 
lipids or modulating TH2 versus TH1 
lymphocyte responses in the vasculature.
    Mooijaart et al. showed that baseline 
apoE levels were directly associated 
with change in C-reactive protein 
(CRP) levels over time and suggested 
that this provided evidence for apoE 
in promoting inﬂ  ammation in a causal 
relationship with CVD. However, use of 
a low-sensitivity CRP assay, with almost 
20% of levels below the detection for 
this assay, combined with potential bias 
in reporting change in CRP levels only 
in the lowest CRP quartile, suggest the 
need for more rigorous assessment of 
this claim. Furthermore, plasma levels 
of both apoE and CRP are largely liver 
derived and could be regulated in a 
similar fashion by hepatic-directed 
factors [16].  
    Measurement of diverse and 
more speciﬁ  c measures of innate 
and adaptive immunity as well as 
additional inﬂ  ammatory markers in 
the full cohort would have provided 
more robust evidence for a link to 
inﬂ  ammation. However, expansion of 
such correlative data would not address 
issues of causality, as the relationship 
of plasma apoE with inﬂ  ammatory 
markers may purely reﬂ  ect its 
association with remnant atherogenic 
lipoproteins rather than any causal 
relationship. Experimental studies of 
the administration of apoE to humans, 
perhaps in speciﬁ  c settings of modest 
evoked inﬂ  ammation, will provide the 
strongest evidence for pro- or anti-
inﬂ  ammatory effects of plasma apoE in 
humans. 
  Conclusion
    These recent papers by Mooijaart et al. 
and Elzen et al. provide new impetus for 
addressing several key questions relating 
to apoE function in atherosclerosis and 
as a plasma biomarker of CVD risk (Box 
1). In summary, apoE has been the 
focus of intense interest with regard to 
atherosclerosis and CVD for more than 
two decades. Despite that, there is a 
remarkable paucity of data from human 
studies that link plasma apoE levels to 
CVD events. Mooijaart et al. are to be 
commended for addressing the question 
of the relationship between apoE and 
CVD.  Their conclusions ﬂ  y in the face 
of the conventional wisdom regarding 
apoE and atherosclerosis and should 
spark substantial additional inquiry into 
the roles of apoE in atherosclerosis and 
CVD in humans.   
  Box 1. Key Questions 
about ApoE Function in 
Atherosclerosis and about 
ApoE as a Plasma Biomarker of 
CVD Risk 
    •  Are plasma apoE levels independent 
positive predictors of CVD events in 
other cohorts?   
    •  Could apoE levels be a predictor 
of “residual risk” in statin-treated 
patients?  
    •  Does plasma apoE simply serve as a 
surrogate for atherogenic remnant 
particles?  
    •  Does apoE in the HDL fraction have a 
different relationship to CVD than total 
plasma apoE levels?   
    •  Does apoE have distinct lipoprotein-
independent functions in humans in 
vivo?   
    •  What is the impact of apoE’s lipid 
antigen-presenting functions in 
atherosclerosis? 
    •  What is the net impact of macrophage 
apoE in modulating atherosclerosis?  
    •  What is the relevance of emerging 
studies that show a role for apoE in 
promoting adult obesity and insulin 
resistance [17–19]? 
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